Nku Nrs255 - E3 -Drugs Effecting Blood Coagulation

Front 1

Drug used for the prevention of acute cardiac events during transluminal coronary angioplasty when used in conjunction with heparin an aspirin; early treatment of unstable angina and non-Q-wave myocardial infarction (MI)
Decrease responsiveness and aggregation of platelets.

Back 1

abciximab
(Antiplatelet Agent)
(route: IV)

Front 2

Drug used for the reduction of the incidence of TIAs and strokes in men; reduction of the risk of death or nonfatal MI in patients with a past history of MI or angina.
Decrease responsiveness and aggregation of platelets.

Back 2

aspirin
(Antiplatelet Agent)
(route: PO)

Front 3

Drug used for the treatmemnt of patients who are at risk for ischemic events; patients with a history of MI, peripheral artery disease or ischemic stroke; patients with acute coronary syndrome.
Decrease responsiveness and aggregation of platelets.

Back 3

clopidrogrel
(Antiplatelet Agent)
(route: PO)

Front 4

Drug used for the treatment of acute coronary syndrome; prevention of ischemic episodes in patients undergoing percutaneous coronary interventions.
Decrease responsiveness and aggregation of platelets.

Back 4

eptifibatide
(Antiplatelet Agent)
(route: IV)

Front 5

Drug used for the reduction of the risk of thrombotic stroke in patients with TIAs or history of stroke who are intolerant to aspirin therapy.
Decrease responsiveness and aggregation of platelets.

Back 5

ticlopidine
(Antiplatelet Agent)
(route: PO)

Front 6

Drug used for the lysis of pulmonary emboli; treatment of coronary thrombosis; for clearing occluded intravenous catheters.
Activates the natural anti-clotting system: conversion of plasminogen to plasmin.

Back 6

urokinase
(Thrombolytic Agent)
(route: IV)

Front 7

Drug used for treatment of MI, acute pulmonary embolism and acute ischemic stroke; restoration of function in occluded central venous access devices.
Activates the natural anti-clotting system: conversion of plasminogen to plasmin.

Back 7

alteplase
(Thrombolytic Agent)
(route: IV)

Front 8

Drug for the prevention of DVT that may lead to pulmonary embolism after abdominal surgery or hip replacement; treatment of unstable angina and non-Q-wave MI.
Inhibits thrombus and clot formation by blocking factors Xa and IIa

Back 8

dalteparin
(Low Molecular-Weight Heparin)
(route: SQ)

Front 9

Drug for the prevention of DVT that may lead to pulmonary embolism after hip replacement or abdominal surgery; with warfarin to treat acute DVT or PE; prevention of ischemic complications of unstable angina or non-Q-wave MI; prevention of DVT in patients with severely restricted mobility due to illness.
Inhibits thrombus and clot formation by blocking factors Xa and IIa

Back 9

enoxaparin
(Low Molecular-Weight Heparin)
(route: SQ)

Front 10

Drug for the treatment of excessive bleeding in hyperfibrinolytic states; prevention of recurrence of bleeding with subarachnoid hemorrhage; sometimes used for treatment of attacks of hereditary angioedema.

Back 10

aminocaproic acid
(Hemostatic Agent)
(route: IV or PO)

Front 11

Drugs that alter platelet aggregation and the formation of the platelet plug.

Back 11

Anti-platelet Drugs

Front 12

Drugs that interfere with the clotting cascade and thrombin formation.

Back 12

Anticoagulants

Front 13

Drugs that breakdown the thrombus or clot that has been formed by stimulating the plasmin system.

Back 13

Thrombolytic Agents

Front 14

Drug used for prevention of thromboembolism in patients with artificial heart valves when used in combination with warfarin; aids in diagnosis of CAD in patients who cannot exercise; may be used in treatment of angina. (USDA says "possibly effective").
Decrease responsiveness of aggregation of platelets.

Back 14

dipyridamole
(Antiplatelet Agent)
(route: PO, IV)

Front 15

Drug used along with aspirin to prevent serious or life-threatening problems with the heart and blood vessels in people who have had a heart attack or severe chest pain and have been treated with angioplasty.Inhibits platelet activation and aggregation.

Back 15

prasugrel
(Antiplatelet Agent)
(route: PO)

Front 16

Drug that causes a decrease in the production of vitamin K dependent clotting factors in the liver. For treatment of patients with atrial fibrillation, artificial heart valves, or vascular damage making susceptible to thrombosis and embolus formation

Back 16

wafarin
(Anticoagulant)
(route: PO)

Front 17

Drug that blocks the formation of thrombin from prothrombin. For prevention and treatment of venous thrombosis, pulmonary embolus, atrial fibrillation with embolization; preventing of clotting in blood samples, dialysis and venous tubing; diagnosis and treatment of disseminated intravascular coagulation (DIC).
Blocks formation of thrombin from prothrombin.

Back 17

heparin
(Anticoagulant)
(route: IV, SQ)

Front 18

Drug for the prevention and treatment of venous thromboembolitic events following surgery for hip fracture, hip replacement, or knee replacement; used with warfarin when appropriate.
Inhibits factor Xa and blacks clotting cascade preventing clot formation.

Back 18

fondaparinux
(Anticoagulant)
(route: SQ)

Front 19

Drug for treatment of heparin-induced thrombocytopenia associated with thromboembolic disease (rare allergic reaction to heparin)
Directly inhibits thrombin.

Back 19

lepirudin
(Anticoagulant adjunctive therapy)
(route: IV)

Front 20

Protein involved with the breakdown of blood clots found on endothelial cells lining blood vessels. As an enzyme, it catalyzes the conversion of plasminogen to plasmin.

Back 20

tPA
(Tissue Plasminogen Activator)
(Thrombolytic Agent)